No Data
No Data
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $72
Oppenheimer Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)
Tarsus Pharmaceuticals Insider Sold Shares Worth $1,163,050, According to a Recent SEC Filing
Insider Sale: Chief Commercial Officer of $TARS Sells 3,557 Shares
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
Tarsus Pharmaceuticals Specializes in Developing Treatments for Eye-Care Diseases >TARS